Full Press Release Details
Nephros Appoints Daron Evans to Board of Directors
RIVER EDGE, NJ, November 29, 2013 /PR Newswire-FirstCall/ -
Nephros, Inc. (OTC Bulletin Board: NEPH), a commercial stage medical device company that develops and sells high performance liquid
purification ultrafilters, announced today the appointment of Daron Evans to its Board of Directors. Mr. Evans replaces James S.
Scibetta who will be leaving the Board effective December 31, 2013. Mr. Evans was also named a member of the Audit Committee.
Mr. Evans is a life sciences executive with over 20 years of
financial leadership and operational experience. Mr. Evans is currently a Partner at The Highland Group, an operational consulting
practice that partners with industrial clients to deliver targeted results, and a Director on the Board of Zumbro Discovery, an
early stage company developing a novel therapy for resistant hypertension. Mr. Evans was most recently Chief Financial Officer
of Nile Therapeutics, Inc., from 2007 until its merger with Capricor, Inc. in November 2013. From 2006 to 2007, he was Director
of Business Assessment for Vistakon, a division of Johnson & Johnson Corp. From 2004 to 2006, he was Associate Director of
Portfolio Mgmt & Business Analytics at Scios, Inc. after its acquisition by Johnson & Johnson Corp. Mr. Evans was a co-founder
of Applied Neuronal Network Dynamics, Inc. and served as its President from 2002 to 2004. From 1995 to 2002, Mr. Evans served in
various roles at consulting firms Arthur D. Little and Booz Allen & Hamilton. Mr. Evans is the author of four U.S. patents.
Mr. Evans received his Bachelor of Science in Chemical Engineering from Rice University, his Master of Science in Biomedical Engineering
from a joint program at the University of Texas at Arlington and Southwestern Medical School and his MBA from the Fuqua School
of Business at Duke University.
"I am very pleased to welcome Daron to Nephros' Board
of Directors," stated John C. Houghton, CEO of Nephros. "Daron's extensive operational and business development
experience will be a welcome complement to the Board."
"I am very impressed with the Nephros team and the wide
range of commercial opportunities for the company's products," stated Mr. Evans. "I look forward to being an
active member of the Board as Nephros seeks to capitalize on these opportunities."
Nephros is a commercial stage medical device company that develops
and sells high performance liquid purification filters. Our filters, which we call ultrafilters, are primarily used in dialysis
centers and healthcare facilities for the production of ultrapure water and bicarbonate.
We were founded in 1997 by healthcare professionals affiliated
with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize an alternative method to hemodialysis
(HD). In 2009, we began to extend our filtration technologies to meet the demand for liquid purification in other areas, in particular
Presently, we offer seven types of ultrafilters for sale to
customers in four markets:
For more information about Nephros, please visit the company's
website at www.nephros.com
Forward-Looking Statements
This press release contains certain "forward-looking statements."
Such statements include statements that are not historical facts, including statements which may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially
from the expectations contained in the forward looking statements.
Factors that may cause such differences include, but are not
limited to, the risks that:
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements, including the forward-looking statements in this press release,
is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2012
and our other periodic reports filed with the SEC. We urge you to read those documents free of charge at the SEC's web site
at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information,
future events or otherwise, except as required by law.